Fate Therapeutics appoints Yuan Xu, Ph.D. to Board of Directors

FATE THERAPEUTICS INC

Board expanded from 9 to 10 directors; Yuan Xu appointed as Class II director effective August 3, 2021.
Dr. Xu granted option to purchase 7,501 shares and RSUs for 4,744 shares, vesting over 3 years.
Dr. Xu previously CEO of Legend Biotech, led cilta-cel development and partnership with Janssen.
Over 25 years biopharma experience including senior roles at Merck, Gilead, and Novartis.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Yuan Xu

Class II director

FATE · FATE THERAPEUTICS INC

Effective: 2021-08-03
Filed: August 4, 2021, 7:59 PM ET

On August 3, 2021, the Board appointed Yuan Xu, Ph.D. to the Board as a Class II director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yuan Xu was appointed as Class II director at FATE THERAPEUTICS INC.

Action: appointed
Role: Class II director

Exact text from the filing

On August 3, 2021, the Board appointed Yuan Xu, Ph.D. to the Board as a Class II director.

View on SEC.gov

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-21-235830

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.